As Indonesia’s Regulatory Body Authorizes Another Chinese Vaccine, There is Dramatic Turnaround in COVID-19 Delta Variant Cases

Indonesia’s food and drug regulatory authority (BPOM) authorized the use of a COVID-19 vaccine produced in China on Thursday. Known as “Zifivax, the product is produced by a unit of China’s Chongqing Zhifei Biological Products. The vaccine is now accepted on an emergency use basis for the world’s fourth most populous nation of 275 million people. According to BPOM’s head Penny Lukito, the protein-recombinant vaccine is administered three times in three months with a reported efficacy rate of 815%—77.47% against the Delta variant of SARS-CoV-2. In parallel, Indonesia has experienced a dramatic turnaround—for the good—with a marked decline in COVID-19 cases.  Is Indonesia overcoming the pandemic?  And if so, how are they accomplishing this?

With a report recently in Reuters and in the Chinese media, TrialSite provides a brief breakdown of this most recently authorized vaccine.  We also update the network that Indonesia has experienced a dramatic reduction in cases. TrialSite has reported that several treatments have been in use, at least in certain segments of society, including ivermectin.  TrialSIte has a team in Indonesia investigating possible factors involved with ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee